CHU Grenoble Alpes
Grenoble, 38000, France
NCT Number: NCT06250348
The aim of the study is to see if endogenous exhaled Nitric Oxyde (eNO) concentrations measured are significantly higher in ARDS patients admitted in ICU ; compared to control subjects in good health with no lung disease or global inflammation, operated under general anesthesia (i.e. intubated and ventilated) for thyroid or parathyroid.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Grenoble, 38000, France
The measurement of endogenous exhaled NO is monitored using a laser spectrometer machine connected to the expiratory circuit of the respirator. The measure is non-invasive and made by sampling expiratory gaz like for capnography.
In control subjects, the measurement period corresponds to the first ten minutes after induction of anesthesia (with intubation) before surgical incision.
In ARDS patients in intensive care, the measurement of eNO is made in the first twenty-four hours after intubation and ventilation of the patient with mechanical respirator.
The primary endpoint is a significantly higher eNO concentration in patients suffering from Acute Respiratory Distress Syndrome (ARDS).
Secondary endpoints will assess correlations between eNO concentrations and usual ARDS severity criteria: PaO2/FiO2; ventilator-free days; length of stay in intensive care and all-cause hospital mortality at 30 days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A sample of exhaled gases is taken from the expiratory part of the respirator circuit (same way as a capnometry measurement). A laser spectrometer continuously and non-invasively monitors online the concentrations of endogenous NO exhaled by patients.
Time frame: Measurement of eNO over a period of 10 minutes just after induction of anesthesia
The primary endpoint is a significantly higher eNO concentration in ARDS patients.
Time frame: Measurement of eNO over a period of 10 minutes within the first 24 hours after intubation
ARDS severity criteria are: Partial arterial pressure of oxygen divided by inspired fraction of oxygen (PaO2/FiO2); ventilator-free days; length of stay in intensive care and all-cause hospital mortality at 30 days.
University Hospital, Grenoble
Other
Acronym: ENOBARDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04115514
ARDS, Human, Endocrine System Diseases
Edina, Minnesota, United States
View Trial DetailsNCT05074758
ARDS, Human, COVID-19 Acute Respiratory Distress Syndrome
Paris, France
View Trial DetailsNCT04444609
ARDS, Human, COVID-19
London, United Kingdom
View Trial DetailsNCT05148026
ARDS, Human, Acute Kidney Injury
Monza, Italy
View Trial Details